Completed PHASE1 INTERVENTIONAL 4-arm NCT00999336

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.

Sponsor: Merck Sharp & Dohme LLC

Conditions Renal Impairment

Interventions Betrixaban

Updated 9 times since 2017 Last updated: Oct 13, 2022 Started: Jul 31, 2009 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Impairment and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1
Sep 2023 — Dec 2023 [monthly]

Completed PHASE1
Jun 2022 — Sep 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Portola Pharmaceuticals

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany